Payment overview · 2025
General Payments
$159.81
10 reported records · 4 companies
Healthcare provider profile · identity verified
Jack M Shields, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BRIDGETON, NJ · NPI 1730119934
Verified facts
What the public records show
CMS Open Payments records show Jack M Shields, M.D. received $159.81 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 41.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.91 | 41.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.68 | 38.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.41 | 10.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.81 | 9.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $159.81 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.82 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.82 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.03 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 459 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 451 | 121 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 382 | 107 |
| Metformin Hcl | Metformin Hcl | 314 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 256 | 70 |
| Lisinopril | Lisinopril | 243 | 61 |
| Furosemide | Furosemide | 223 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 194 | 57 |
| Omeprazole | Omeprazole | 171 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 45 |
| Simvastatin | Simvastatin | 162 | 45 |
| Losartan Potassium | Losartan Potassium | 158 | 44 |
| Gabapentin | Gabapentin | 155 | 48 |
| Atenolol | Atenolol | 138 | 38 |
| Eliquis | Apixaban | 127 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 113 | 31 |
| Carvedilol | Carvedilol | 110 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 32 |
| Farxiga | Dapagliflozin Propanediol | 101 | 24 |
| Alprazolam | Alprazolam | 100 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 25 |
| Montelukast Sodium | Montelukast Sodium | 95 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 18 |
| Sertraline Hcl | Sertraline Hcl | 81 | 23 |
| Allopurinol | Allopurinol | 79 | 22 |
| Prednisone | Prednisone | 77 | 53 |
| Valsartan | Valsartan | 77 | 21 |
| Jardiance | Empagliflozin | 72 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 51 |
| Buspirone Hcl | Buspirone Hcl | 66 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 60 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 16 |
| Azithromycin | Azithromycin | 57 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 16 |
| Ozempic | Semaglutide | 51 | suppressed |
| Potassium Chloride | Potassium Chloride | 50 | 14 |
| Donepezil Hcl | Donepezil Hcl | 49 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 13 |
| Nateglinide | Nateglinide | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Lorazepam | Lorazepam | 46 | 15 |
| Xarelto | Rivaroxaban | 46 | 11 |
| Famotidine | Famotidine | 43 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 38 | 11 |
| Celecoxib | Celecoxib | 37 | 14 |
| Glimepiride | Glimepiride | 37 | 12 |
| Memantine Hcl | Memantine Hcl | 37 | 12 |
| Chlorthalidone | Chlorthalidone | 36 | 14 |
| Ramipril | Ramipril | 36 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 11 |
| Warfarin Sodium | Warfarin Sodium | 35 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 33 | 11 |
| Meloxicam | Meloxicam | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 14 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 12 |
| Valacyclovir | Valacyclovir Hcl | 29 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Repaglinide | Repaglinide | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Metolazone | Metolazone | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Desloratadine | Desloratadine | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Trulicity | Dulaglutide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $159.81 · 10 records | Lilly USA, LLC | JARDIANCE, KRYSTEXXA, MOUNJARO, Ozempic, Rybelsus, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error